ArticleLa Radiologia medica2021
Imaging biomarkers in the diagnosis of salivary gland tumors: the value of lesion/parenchyma ratio of perfusion-MR pharmacokinetic parameters.
Article in La Radiologia medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CT imaging of thyroid cartilage invasion in glottic laryngeal cancer: correlation of traditional semiotics and texture analysis with histopathology.La Radiologia medica · 2026Article
- Quantitative Permeability MRI for Preoperative Differentiation of Warthin Tumors and Malignant Salivary Gland Lesions.Diagnostics (Basel, Switzerland) · 2026Article
- The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Differentiating Salivary Gland Neoplasms Compared with Fine-Needle Aspiration (FNA).Diagnostics (Basel, Switzerland) · 2026Article
- Salivary gland pathologies: evolution in classification and association with unique genetic alterations.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Review
- Imaging of human papilloma virus (HPV) related oropharynx tumour: what we know to date.Infectious agents and cancer · 2023Review
- Radiomics in Lung Metastases: A Systematic Review.Journal of personalized medicine · 2023Review
- Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel.Cancers · 2022Review
- Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams.Journal of personalized medicine · 2022Review
- Imaging Features of Post Main Hepatectomy Complications: The Radiologist Challenging.Diagnostics (Basel, Switzerland) · 2022Review
- Role of Texture Analysis in Oropharyngeal Carcinoma: A Systematic Review of the Literature.Cancers · 2022Review
- Lymph Nodes Evaluation in Rectal Cancer: Where Do We Stand and Future Perspective.Journal of clinical medicine · 2022Review
- Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.Japanese journal of radiology · 2022Review
- Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma.Infectious agents and cancer · 2022Article
- Advanced Magnetic Resonance Imaging (MRI) Techniques: Technical Principles and Applications in Nanomedicine.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeMorphologic magnetic resonance imaging (MRI) for characterization of salivary gland tumors has limited utility, and the use of perfusion MRI data in the clinical setting is controversial. We examined the potential of tissue-normalized dynamic contrast-enhanced (DCE) MRI pharmacokinetic parameters of salivary gland tumors as imaging biomarkers for characterization and differentiation between benign and malignant lesions. MATERIALS AND
methodsDCE-MR images acquired from 60 patients with parotid and submandibular gland tumors were retrospectively reviewed. Pharmacokinetic parameters as transfer constant (Ktrans), rate constant (Kep), extracellular space volume (Ve), fractional plasma volume (Vp), and AEC (area of all times enhancement curve) were measured on both the lesion and the normal contralateral salivary gland parenchyma. Lesion/parenchyma ratio (L/P) for each parameter was calculated.
resultsFive groups of lesions were identified (reference: histopathology): pleomorphic adenomas(n = 20), Warthin tumors(n = 16), other benign entities(n = 4), non-Hodgkin lymphomas(n = 4), and malignancies(n = 16). Significant differences were seen for mean values of L/PKtrans (higher in malignancies), L/PKep (lower in adenomas than Warthin tumors), L/PVe (lower in Warthin tumors and lymphomas), L/PVp (higher in Warthin tumors and malignancies than adenomas), and L/PAEC (higher in malignancies). Significant differences were found between benign and malignant (non-lymphoproliferative) lesions in mean value of L/PKtrans (0.485 and 1.581), L/PVp (1.288 and 2.834), and L/PAEC (0.682 and 1.910). ROC analysis demonstrated the highest AUC (0.96) for L/PAEC, with sensitivity and specificity for malignancy of 93.8% and 97.5% (cutoff value = 1.038).
conclusionLesion/parenchyma ratio of DCE-MRI pharmacokinetic data could be helpful for recognizing the principal types of salivary gland tumors; L/PAEC seems a valuable biomarker for differentiating benign from malignant tumors.
Indexed as
Identifiers
34181206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.